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Background: CYP2C19 loss-of-function (LOF) alleles affect clinical outcome of clopidogrel therapy in patients treated with 1st-generation DES. 
However, no data exist on the impact of CYP2C19 LOF alleles on clinical outcome in newer-generation DES era.
methods: The effects of CYP2C19 genotypes were evaluated on clinical outcome of clopidogrel therapy in 2073 patients treated with either PCI 
using 1st-generation DES (SES and PES, n=1355) or newer-generation DES (EES and ZES, n=718). The primary clinical outcome was major cardiac 
and cerebrovascular event (MACCE) comprising all-cause death, non-fatal myocardial infarction, or stroke during 1 year of follow-up.
results: CYP2C19 LOF alleles were associated with higher risk of MACCE in patients treated with 1st-generation DES (hazard ratio [HR], 2.211; 
95% confidence interval [CI], 1.075-4.547; P=0.035). CYP2C19 LOF alleles were not associated with primary outcome in those treated with newer-
generation DES (HR, 0.730; 95% CI, 0.354-1.506; P=0.450). There was no difference of P2Y12 reaction unit between the groups. Multivariate 
analysis demonstrated that there was no significance in newer-generation DES (adjusted HR, 0.627; 95% CI, 0.303-1.297; p=0.208), although 
CYP2C19 LOF alleles were an independent predictor of MACCE in patients with first-generation DES (adjusted HR, 2.058; 95% CI, 1.008-4.203; 
p=0.048).
conclusions: CYP2C19 LOF alleles may not affect clinical outcome of clopidogrel therapy in patients treated with newer-generation DES.
 
